Cell signaling

Nursa CEO/Founder Curtis Anderson Named to Board of Directors for Utah Chapter of HIMSS

Retrieved on:

Thursday, October 5, 2023

Practice Management, Telemedicine, Virtual Medicine, Nursing, Managed Care, General Health, Health, Hospitals, Other Health, HIMSS, Hope, Communication, Job satisfaction, Anderson, Utah State University, Healthcare Information and Management Systems Society, Sponsor (commercial), Cell signaling

Nursa , a nationwide platform that exists to put a nurse at the bedside of every patient in need, today announces its CEO and founder, Curtis Anderson, has been named to the board of directors of the Utah Chapter of the Healthcare Information and Management Systems Society (UHIMSS).

Key Points:

Nursa , a nationwide platform that exists to put a nurse at the bedside of every patient in need, today announces its CEO and founder, Curtis Anderson, has been named to the board of directors of the Utah Chapter of the Healthcare Information and Management Systems Society (UHIMSS).
Anderson joins the statewide leadership coalition for the advancement and management of healthcare information and technology as Sponsorship Chair.
The event showcased the latest advancements and solutions that are shaping healthcare communities within Utah and the nation at large.
Nursa is a locally driven, national platform that partners with any organization that needs nurses to deliver the best patient care.

Nursa Partners with American Red Cross on Nurse Staffing for Disaster Relief Sites

Retrieved on:

Tuesday, August 29, 2023

Nursa , a nationwide platform that exists to put a nurse at the bedside of every patient in need, today announced a partnership with the American Red Cross to aid in staffing disaster relief sites with nurse volunteers.

Key Points:

Nursa , a nationwide platform that exists to put a nurse at the bedside of every patient in need, today announced a partnership with the American Red Cross to aid in staffing disaster relief sites with nurse volunteers.
Through this partnership, Nursa’s fast-growing community of more than 95,000 nurses can apply to volunteer with the Red Cross directly through Nursa.
“As a Red Cross nurse, I have the privilege of working with those impacted by a disaster and to assist them with their health-related recovery needs,” said American Red Cross nurse volunteer Karen Younger.
And being a Red Cross nurse is also a wonderful opportunity to form new and lasting friendships with other disaster responders.”
Each year, Red Cross volunteers help respond to more than 60,000 disasters.

Nursa Leverages $80M Series B to Expand C-Suite and Address Rising Healthcare Staffing Shortage and Financial Crisis

Retrieved on:

Tuesday, August 22, 2023

With the addition of experienced Chief Product, Revenue and Technology Officers, Nursa is diversifying its expertise in order to further address the industry’s rising financial and nursing deficits.

Key Points:

With the addition of experienced Chief Product, Revenue and Technology Officers, Nursa is diversifying its expertise in order to further address the industry’s rising financial and nursing deficits.
With federal incentives gone, solving nurse staffing shortages without additional financial loss is nearly impossible.
Nursa is a locally driven, national platform, working with any organization that needs nurses to deliver the best patient care.
To learn more about Nursa and its mission to put a nurse at the bedside of every patient in need, please visit Nursa.com .

Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting

Retrieved on:

Thursday, February 16, 2023

Trial of the century, Lead, HPV, Cue, Cell signaling, Head, Selective, Nature, Patient, Signal transduction, University, Research, Modes of toxic action, Concept, Poster, Kennedy Institute, Kennedy Institute of Ethics Journal, Vaccine

The research is part of a strategic research collaboration that Cue Biopharma initiated with Dr. Michael Dustin’s laboratory at the University of Oxford in May 2020 to determine the molecular mechanisms underlying the activity of the company’s interleukin 2 (IL-2) based CUE-100 series of biologics.

Key Points:

The research is part of a strategic research collaboration that Cue Biopharma initiated with Dr. Michael Dustin’s laboratory at the University of Oxford in May 2020 to determine the molecular mechanisms underlying the activity of the company’s interleukin 2 (IL-2) based CUE-100 series of biologics.
“The data continue to support the differentiated mechanism of action of Cue Biopharma’s Immuno-STAT CUE-100 series of biologics, by uniquely mimicking the natural process of immune synapse formation,” said Jesusa Capera-Aragones, Ph.D., post-doctoral researcher, Dustin laboratory of the Kennedy Institute at the University of Oxford.
“By simultaneously presenting a targeted antigen and the immunostimulatory molecule IL-2, Cue Biopharma’s biologics enable the specific and simultaneous engagement of IL-2 and T cell receptors, as it would occur in nature.
Dr. Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma, added “We are very pleased with the research and collaboration with Dr. Dustin’s laboratory of the Kennedy Institute at the University of Oxford.

Healthcare Heroes Celebrated with Nursa™ Thank You Party

Retrieved on:

Wednesday, May 11, 2022

American Securities, SALT, Fatigue, Nursing, Salt Lake, Patient, Grand America Hotel, Freedom, Anxiety, Friends, LPN, CEO, CNA, Hospital, Medicine, Cell signaling

SALT LAKE CITY, May 11, 2022 /PRNewswire/ -- A giant "Thank You" party celebrated Salt Lake City-area healthcare workers and kicked off National Nurses Week.

Key Points:

SALT LAKE CITY, May 11, 2022 /PRNewswire/ -- A giant "Thank You" party celebrated Salt Lake City-area healthcare workers and kicked off National Nurses Week.
The family-friendly party was hosted by Nursa, a Salt Lake City-based healthcare staffing technology company .
Nurses and other healthcare professionals have faced enormous strain and faced stress, anxiety, and fatigue during the pandemic.
That's why a major focus of the party was on wellness and self-care for healthcare workers.

DGAP-News: Andera Partners' Portfolio Company T-knife Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor Therapies

Retrieved on:

Tuesday, August 3, 2021

Medical specialties, Branches of biology, Clinical medicine, Immunology, Immune system, Cell signaling, T-cell receptor, T cell, TCR, Kite Pharma, Short course immune induction therapy, Andera Partners, T-knife Therapeutics, the HuTCR platform, ANDERA PARTNERS, T-KNIFE THERAPEUTICS, THE HUTCR PLATFORM

T-knife plans to use proceeds from the financing to expand its scientific team, increase manufacturing capacity and advance its pipeline of T-cell receptor (TCR) engineered T cell therapies (TCR-T).

Key Points:

T-knife plans to use proceeds from the financing to expand its scientific team, increase manufacturing capacity and advance its pipeline of T-cell receptor (TCR) engineered T cell therapies (TCR-T).
"We are pleased to be progressing TK-8001 toward the clinic and to advance our broader portfolio of product candidates."
"We are highly encouraged by the progress being made at T-knife to advance its important next-generation therapies."
T-knife is a next-generation T-cell receptor (TCR) company developing a pipeline of therapeutics for solid tumor patients.

TScan Therapeutics to Present Discovery of T Cell Targets for COVID-19 at the Cell-Mediated Therapies for Infectious Disease Summit

Retrieved on:

Wednesday, July 21, 2021

Branches of biology, Life sciences, Medical specialties, Immune system, Immunology, Biotechnology, Cell signaling, Cancer immunotherapy, Biopharmaceutical, T cell, T-cell receptor, Kite Pharma

The Company publishedthese targets in an October 2020 paper in Immunity , showcasing the power of the companys high-throughput T-cell target discovery platform, TargetScan.

Key Points:

The Company publishedthese targets in an October 2020 paper in Immunity , showcasing the power of the companys high-throughput T-cell target discovery platform, TargetScan.
The presentation will also feature in vitro data comparing several polyepitope T-cell vaccine candidates based on the Companys novel T cell target discoveries.
The Company has also licensed the TCR sequences discovered during this research to Poseida Therapeutics, Inc. to develop allogeneic T-cell therapies for COVID-19.
TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer.

Aptinyx to Participate in William Blair Biotech Focus Conference 2021

Retrieved on:

Monday, July 12, 2021

Biotechnology, Pharmaceutical, Health, Branches of biology, Biology, Glutamate, Cell signaling, NMDA receptor, Neuroplasticity

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in the Updates in Neuropysch panel discussion at the William Blair Biotech Focus Conference on Thursday, July 15 at 12:00 p.m.

Key Points:

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in the Updates in Neuropysch panel discussion at the William Blair Biotech Focus Conference on Thursday, July 15 at 12:00 p.m.
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders.
Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulaterather than block or over-activateNMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication.
The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment.

BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor - peptide-HLA interactions

Retrieved on:

Wednesday, July 7, 2021

Branches of biology, Medical specialties, Immune system, Immunology, Single-pass transmembrane proteins, Cell signaling, T-cell receptor, T cell, Human leukocyte antigen, ImmTAC, MHC restriction

BASEL, Switzerland and TBINGEN, Germany, July 7, 2021 /PRNewswire/ -- BioCopy AG announces a collaboration with Immatics N.V. (NASDAQ: IMTX) "Immatics" in the field of characterization of T cell receptors (TCRs).

Key Points:

BASEL, Switzerland and TBINGEN, Germany, July 7, 2021 /PRNewswire/ -- BioCopy AG announces a collaboration with Immatics N.V. (NASDAQ: IMTX) "Immatics" in the field of characterization of T cell receptors (TCRs).
For this reason, BioCopy has developed an innovative technology that enables high-throughput screening of T cell receptors for binding to a wide variety of peptide-HLA complexes.
With this technology BioCopy is contributing a safety screening for novel TCR-based cancer cell therapies.
The goal of this collaboration is to enable the characterization of more than 5,000 different TCR-peptide-HLA interactions simultaneously.

Aptinyx to Participate in Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit

Retrieved on:

Tuesday, July 6, 2021

Biotechnology, Pharmaceutical, Health, Clinical trials, Branches of biology, Biology, Cell signaling, Glutamate, NMDA receptor

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that management will participate in a fireside chat at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit on Tuesday, July 13 at 3:40 p.m.

Key Points:

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that management will participate in a fireside chat at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit on Tuesday, July 13 at 3:40 p.m.
A live webcast of the event will be available to clients of Cowen.
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders.
Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulaterather than block or over-activateNMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication.